TITLE:
Hydroxycarbamide and Sickle Cell Disease in a Context of Malaria Endemicity in Sub-Saharan Africa: Experience of the Sickle Cell Disease Center in Bamako, Mali
AUTHORS:
Yeya dit Sadio Sarro, Mahamoud Mahamadou Koureichi, Mariam Kanta, Moussa Coulibaly, Elmaouloud Hamidou Sorry Diallo, Drissa Diabaté, Mahamadou Ouologuem, Yacouba Fofana, Diakalia Siaka Berthé, Sekou Kéné, Boubacari Ali Touré, Aldiouma Guindo
KEYWORDS:
CRLD, Sickle Cell Disease, Hydroxyurea, Malaria
JOURNAL NAME:
Open Journal of Epidemiology,
Vol.16 No.4,
November
18,
2026
ABSTRACT: Introduction: Sickle cell disease and malaria represent both major health problems in sub-Saharan Africa. This study aims to evaluate the impact of hydroxycarbamide or hydroxyurea treatment on the incidence and time to onset of malaria in children with sickle cell disease in Mali. Methodology: This was a retrospective cohort study conducted at the Research and Control Center for Sickle Cell Disease (CRLD) in Bamako. It included 100 children with sickle cell disease (aged 1 to 17 years) and compared data between those treated with hydroxyurea (n = 52) and those not treated (n = 48). Follow-up started at the date of registration at the center; the event of interest was the first episode of malaria, and children without malaria were censored at their last recorded event. Log-rank tests were used for comparisons, and a Cox model was used to identify factors associated with the occurrence of malaria. Results: All children who did not develop malaria (31/31) were receiving hydroxyurea, while only 30% (21/69) of those who did (p Conclusion: In this cohort, hydroxyurea was associated with a lower incidence of malaria and a longer time to its onset in children with sickle cell disease. Because of the observational design and the residual biases described in the manuscript, these results do not establish a causal relationship, but they support wider access to this treatment and its prospective evaluation in malaria-endemic areas.